Spirovant Presents Preclinical Data Showing SP-101 Restores CF Transmembrane Conductance Regulator Function at the 2021 North American Cystic Fibrosis Conference
Philadelphia, PA, November 4, 2021 – Spirovant Sciences, a gene therapy company developing treatments and cures for inherited respiratory diseases including cystic fibrosis (CF), today presented SP-101, an investigational novel recombinant adeno-associated virus (AAV) gene therapy selected for its tropism to human airway epithelia, at the 2021 North American Cystic Fibrosis Conference (NACFC 2021). In oral and […]
Spirovant to Present SP-101 Data at the 2021 North American Cystic Fibrosis Conference
Philadelphia, PA, October 28, 2021 – Spirovant Sciences, a gene therapy company developing treatments and cures for inherited respiratory diseases including cystic fibrosis (CF), today announced that it will be delivering oral and poster presentations highlighting pre-clinical data for its compound, SP-101, at the 2021 North American Cystic Fibrosis Conference (NACFC 2021), November 2-5. SP-101, an investigational […]
FDA Grants Spirovant Sciences Orphan Drug and Rare Pediatric Disease Designations for SPIRO-2101 for Treatment of Cystic Fibrosis
PHILADELPHIA, Sept. 24, 2020 /PRNewswire/ — Spirovant Sciences, a gene therapy company developing treatments and cures for genetic lung diseases including cystic fibrosis, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug and Rare Pediatric Disease Designations to its lead product candidate, SPIRO-2101, for the treatment of cystic fibrosis. SPIRO-2101, an […]
Spirovant Sciences Appoints Roland Kolbeck, PhD, as Chief Scientific Officer
PHILADELPHIA, May 13, 2020 /PRNewswire/ — Spirovant Sciences, a gene therapy company developing treatments and cures for genetic lung diseases including cystic fibrosis (CF), today appointed Roland Kolbeck, PhD, as Chief Scientific Officer. Dr. Kolbeck is an accomplished biotech executive, specializing in respiratory sciences and drug discovery. His career spans more than 20 years of […]
Philadelphia gene therapy company battling cystic fibrosis gets a new owner
Philadelphia gene therapy company Spirovant Sciences changed owners twice in 2019— including being acquired by Sumitomo Dainippon Pharma of Japan last week as part of a $3 billion deal — and its CEO couldn’t be happier.
Sumitomo Dainippon Pharma and Roivant Sciences Sign Definitive Agreement for Strategic Alliance
Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) announced today that it has completed the procedure related to stock transfers, etc. and for the formation of a Strategic Alliance with Roivant Sciences (Head Offices: London and Basel; Founder & CEO: Vivek Ramaswamy) as of December 27, 2019. […]
How a small Philadelphia gene therapy company became part of a $3B deal
The article in the Philadelphia Business Journal features how Spirovant is developing two gene therapies to treat, and potentially cure, cystic fibrosis.
Sumitomo Dainippon Pharma and Roivant Sciences Sign Definitive Agreement for Strategic Alliance
Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506), a leading Japanese pharmaceutical company, and Roivant Sciences Ltd., a technology-enabled healthcare company, today announced that they have signed a definitive agreement for the creation of a novel and broad Strategic Alliance and
<a href="https://spirovant.com/wp-content/uploads/2022/03/NACFC-SP-101_POSTER_Master-9-22-2181-Read-Only-1.pdf">Katherine Excoffon: Delivery of SP-101 restores CFTR function in human CF airway epithelial cultures and drives hCFTRΔR transgene expression in the airways of ferrets. North American Cystic Fibrosis Conference 2021. – Poster</a>
Katherine Excoffon: Delivery of SP-101 restores CFTR function in human CF airway epithelial cultures and drives hCFTRΔR transgene expression in the airways of ferrets. North American Cystic Fibrosis Conference 2021. – Video
